• norsk
    • English
  • English 
    • norsk
    • English
  • Login
View Item 
  •   Home
  • Artikler, rapporter, filmer / Articles, reports, movies
  • Artikkel - fagfellevurdert vitenskapelig / Articles - peer-reviewed
  • View Item
  •   Home
  • Artikler, rapporter, filmer / Articles, reports, movies
  • Artikkel - fagfellevurdert vitenskapelig / Articles - peer-reviewed
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001

Hartz, Ingeborg; Njølstad, Inger; Eggen, Anne Elise
Journal article, Peer reviewed
Thumbnail
View/Open
Hartz, I., (2005) European heart journal..pdf (351.8Kb)
URI
http://hdl.handle.net/11250/134238
Date
2005
Metadata
Show full item record
Collections
  • Artikkel - fagfellevurdert vitenskapelig / Articles - peer-reviewed [1175]
Original version
Hartz, I., Njølstad, I. & Eggen, A.E. (2005). Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001. European heart journal. 26(24), 2673   http://dx.doi.org/10.1093/eurheartj/ehi596
Abstract
Aims To study the implications of European guidelines on the use of antihypertensives and/or lipidlowering

drugs (LLDs) for primary prevention in a Norwegian population.

Methods and results The Tromsø study is a population-based study in the municipality Tromsø, Norway

(from 1974 to till now). This analysis includes 45–79-year-old participants in 2001 (n ¼ 6362, attendance

rate 86%). From the age of 60 years in men and 70 years in women, almost all participants were defined

as high-risk individuals according to the European guidelines, with established cardiovascular disease,

diabetes, or a 10-year risk score of 5%. In the primary prevention subgroup of the 45–64-year-olds,

recommended antihypertensive and/or LLD use would be higher in men only, 42% compared with 12%

on current medication. Among the 65–79-year-olds, .90% would be eligible for antihypertensives

and/or LLDs in both sexes when compared with current treatment rates of ,30%. In total, 40% of all

participants aged 45–79 would be candidates for primary prevention, compared with 15% on current

medication.

Conclusion The implementation of the European guidelines could imply a doubling of the numbers of

Norwegian adults on cardiovascular medication for primary prevention. Contributors to the increase

would be more frequent drug use in men and elderly people, particularly for LLD use.
Description
This is a pre-copy-editing, author-produced PDF of an article accepted for publication in European Heart Journal following peer review. The definitive publisher-authenticated version Hartz, I., Njølstad, I. & Eggen, A.E. (2005). Does implementation of the European guidelines based on the SCORE model double the number of Norwegian adults who need cardiovascular drugs for primary prevention? The Tromsø study 2001. European heart journal. 26(24), 2673 is available online at: dx.doi.org/10.1093/eurheartj/ehi556
Publisher
European Heart Journal

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit
 

 

Browse

ArchiveCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsDocument TypesJournalsThis CollectionBy Issue DateAuthorsTitlesSubjectsDocument TypesJournals

My Account

Login

Statistics

View Usage Statistics

Contact Us | Send Feedback

Privacy policy
DSpace software copyright © 2002-2019  DuraSpace

Service from  Unit